Advertisement
Advertisement
JAZZ
Jazz Pharmaceuticals, Inc.
237.95
USDSponsored
+1.67
+0.71%
Sep 25, 15:58 UTC -4
Closed
After-Market
238.01
+0.06
+0.03%
JAZZ Earnings Reports
Positive Surprise Ratio
JAZZ beat 23 of 43 last estimates.
53%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.23B
/$6.61
Implied change from Q2 26 (Revenue/ EPS)
+1.99%
/+15.76%
Implied change from Q3 25 (Revenue/ EPS)
+9.44%
/-18.70%
Jazz Pharmaceuticals, Inc. earnings per share and revenue
On Aug 03, 2026, JAZZ reported earnings of 5.71 USD per share (EPS) for Q2 26, missing the estimate of 6.29 USD, resulting in a -9.35% surprise. Revenue reached 1.21 billion, compared to an expected 1.14 billion, with a 6.20% difference. The market reacted with a +3.99% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of 6.61 USD, with revenue projected to reach 1.23 billion USD, implying an increase of 15.76% EPS, and increase of 1.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Jazz Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Jazz Pharmaceuticals, Inc. reported EPS of $5.71, missing estimates by -9.35%, and revenue of $1.21B, 6.2% above expectations.
How did the market react to Jazz Pharmaceuticals, Inc.'s Q2 2026 earnings?
The stock price moved up 3.99%, changed from $251.58 before the earnings release to $261.62 the day after.
When is Jazz Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Jazz Pharmaceuticals, Inc.'s next earnings report?
Based on 9
analysts, Jazz Pharmaceuticals, Inc. is expected to report EPS of $6.61 and revenue of $1.23B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.